Fabrication of a phototheranostic nanoplatform for single laser-triggered NIR-II fluorescence imaging-guided photothermal/chemo/antiangiogenic combination therapy

Feng Lu,Ruoyu Sang,Yu Tang,Hui Xia,Jiawei Liu,Wei Huang,Quli Fan,Qi Wang
DOI: https://doi.org/10.1016/j.actbio.2022.08.013
IF: 10.633
2022-01-01
Acta Biomaterialia
Abstract:Phototheranostics that integrates real-time optical imaging and light-controlled therapy has recently emerged as a promising paradigm for cancer theranostics. Herein, a new small molecule dye DPP-BT-TPA with strong emission above 10 0 0 nm and a redox-responsive prodrug camptothecin-combretastatin A4 (CPT-CA4) were designed and successfully synthesized. A multifunctional phototheranostic nanoplatform was then fabricated by encapsulating them within an amphiphilic polymer. The presence of DPP-BT-TPA enabled high-resolution imaging in the second near-infrared window (NIR-II) and efficient photothermal therapy. The prodrug was cleaved by the overexpressed glutathione (GSH) in the tumor microenviron-ment to release the chemotherapeutic drug CPT and the angiogenesis inhibitor CA4. Because this process can be accelerated with elevated temperature, laser-induced hyperthermia was utilized to control the drug release and enhance the therapeutic effect. Tumors in living mice were observed through NIR-II imaging after intravenous injection of the obtained nanoparticles. Improved antitumor efficacy by pho-tothermal/chemo/antiangiogenic combination therapy was achieved with a NIR laser both in vitro and in vivo. This work provides a promising strategy for developing tumor microenvironment responsive and light-controlled theranostic platforms.Statement of significanceFluorescence imaging in the second near-infrared (NIR-II, 10 0 0-170 0 nm) window and near-infrared light-controlled drug release have been recognized as efficient strategies for cancer theranostics. Herein, we present a phototheranostic platform fabricated with a biocompatible NIR-II emissive dye DPP-BT-TPA and a redox-responsive prodrug camptothecin-combretastatin A4 (CPT-CA4). DPP-BT-TPA not only pro-vides high-resolution NIR-II imaging in vivo but also enables efficient photothermal therapy. In addition, the photothermal effect largely accelerates the release of the chemotherapeutic drug CPT and the angio-genesis inhibitor CA4 in the glutathione-overexpressed tumor microenvironment. Thus, the designed pho-totheranostic platform can be used for NIR-II imaging-guided photothermal/chemo/antiangiogenic combi-nation therapy for tumors with a single laser.(c) 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
What problem does this paper attempt to address?